Siemens Fonds Invest GmbH Sells 2,103 Shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX)

Siemens Fonds Invest GmbH reduced its position in shares of IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report) by 78.9% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 563 shares of the company's stock after selling 2,103 shares during the quarter. Siemens Fonds Invest GmbH's holdings in IDEXX Laboratories were worth $241,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also recently modified their holdings of IDXX. Ritholtz Wealth Management boosted its position in shares of IDEXX Laboratories by 43.8% during the 4th quarter. Ritholtz Wealth Management now owns 956 shares of the company's stock valued at $395,000 after acquiring an additional 291 shares during the last quarter. Merit Financial Group LLC bought a new stake in IDEXX Laboratories in the fourth quarter worth $315,000. Sax Wealth Advisors LLC lifted its position in IDEXX Laboratories by 76.3% in the fourth quarter. Sax Wealth Advisors LLC now owns 1,426 shares of the company's stock worth $590,000 after buying an additional 617 shares during the last quarter. Pine Haven Investment Counsel Inc lifted its position in IDEXX Laboratories by 10.5% in the fourth quarter. Pine Haven Investment Counsel Inc now owns 1,075 shares of the company's stock worth $444,000 after buying an additional 102 shares during the last quarter. Finally, Seilern Investment Management Ltd bought a new stake in IDEXX Laboratories in the fourth quarter worth $113,104,000. 87.84% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

A number of analysts recently issued reports on IDXX shares. Bank of America raised their price target on IDEXX Laboratories from $475.00 to $535.00 and gave the stock a "neutral" rating in a research report on Tuesday, February 4th. Barclays raised their price target on IDEXX Laboratories from $481.00 to $520.00 and gave the stock an "overweight" rating in a research report on Tuesday, February 4th. Piper Sandler raised their price target on IDEXX Laboratories from $435.00 to $510.00 and gave the stock a "neutral" rating in a research report on Monday, February 10th. Morgan Stanley raised their price target on IDEXX Laboratories from $548.00 to $558.00 and gave the stock an "overweight" rating in a research report on Monday, May 5th. Finally, StockNews.com upgraded IDEXX Laboratories from a "hold" rating to a "buy" rating in a research report on Friday, May 9th. Three investment analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $524.75.

IDEXX Laboratories Stock Performance

IDXX stock opened at $518.10 on Monday. The company has a quick ratio of 0.95, a current ratio of 1.31 and a debt-to-equity ratio of 0.28. The business's fifty day simple moving average is $431.28 and its two-hundred day simple moving average is $431.45. IDEXX Laboratories, Inc. has a twelve month low of $356.14 and a twelve month high of $545.43. The firm has a market cap of $41.67 billion, a price-to-earnings ratio of 48.56, a PEG ratio of 3.41 and a beta of 1.52.

IDEXX Laboratories (NASDAQ:IDXX - Get Free Report) last released its earnings results on Thursday, May 1st. The company reported $2.96 earnings per share for the quarter, topping analysts' consensus estimates of $2.93 by $0.03. The business had revenue of $998.43 million for the quarter, compared to analyst estimates of $998.25 million. IDEXX Laboratories had a return on equity of 55.82% and a net margin of 22.78%. The business's revenue was up 3.6% compared to the same quarter last year. During the same quarter last year, the firm posted $2.71 earnings per share. Analysts predict that IDEXX Laboratories, Inc. will post 11.93 earnings per share for the current year.

About IDEXX Laboratories

IDEXX Laboratories, Inc develops, manufactures, and distributes products primarily for the companion animal veterinary, livestock and poultry, dairy, and water testing markets in Africa, the Asia Pacific, Canada, Europe, Latin America, and internationally. The company operates through three segments: Companion Animal Group; Water Quality Products; and Livestock, Poultry and Dairy.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.